Monday, February 26, 2018

Nature Reviews Immunology Contents March 2018 Volume 18 Number 3 pp 149-219

If you are unable to see the message below, click here to view.
Nature Reviews Immunology

Quantitative analysis of neutrophil activation using Agilent Seahorse XF Technology

Discover the benefits of measuring neutrophil activation using the XF analyzer! XF Technology provides a quantitative real-time assay for neutrophil activation. Tune in for examples of how this application can be used to examine neutrophil activation, and for a validated protocol.

Watch the webinar to learn more
March 2018 Volume 18 Number 3 Advertisement
Nature Reviews Immunology cover
2016 2-year Impact Factor 39.932 Journal Metrics 2-year Median 29
In this issue
Research Highlights
Focus on: Cancer immunotherapy
Also this month
 Featured article:
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe & Kristen E. Pauken

Can you trust your Antibody? Implications for disease research.

A recent publication in Scientific Reports rigorously tested nine commercially available antibodies for specificity and sensitivity and found that only one, from Cell Signaling Technology, met all validation criteria. Read this open-access article to explore the potentially serious implications of non-specific antibodies and disease research.

Read more now.

Recommend to library
Poster on: CAR T cells in cancer therapy 

Nature Reviews Drug Discovery present this Poster which provides an overview of the different ways to design and produce CAR T cells and the journey that has driven these CAR T cells to FDA approval in 2017. 

Download free today

Produced with support from: 
Lonza Bioscience Solutions 
Do you have a career question?

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today!

Immunotherapy: Direct shot
p149 | doi:10.1038/nri.2018.10
Intratumoural vaccination with immune-enhancing agents eradicates tumour metastases.


Infectious disease: γ δ T cells stop malarial comeback
p150 | doi:10.1038/nri.2018.15
γ δ T cells stop malarial comeback T cells prevent the recurrence of malarial parasitaemia by producing M-CSF.


Immunotherapy: Cytokine boost for CAR T cells
p150 | doi:10.1038/nri.2018.8
Chimeric antigen receptors that provide an antigen-dependent signal 3 to T cells have improved antitumour efficacy.


Tumour immunology: NK cells bring in the troops
p151 | doi:10.1038/nri.2018.14
NK cells recruit cDC1s to the tumour microenviroment by producing the chemokines CCL5 and XCL1.


Microbiota: Pathobiont peacekeepers
p152 | doi:10.1038/nri.2018.11
Pathobiont-specific peripherally derived regulatory T cells have an important role in maintaining gut homeostasis.


Altered self: the not-so-neo-antigens

p152 | doi:10.1038/nri.2018.7
Jedd Wolchok describes a 1996 study by Alan Houghton and colleagues that showed how immune tolerance to self antigens on cancer cells could be overcome.



Nature Reviews Immunology
JOBS of the week
Faculty Member � Cryo-EM
St. Jude Children's Research Hospital (SJCRH)
Postdoctoral Fellow
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Director / Senior Director, Immuno-Oncology Research
Alector LLC
Postdoctoral Fellow Position Available
National Institutes of Health (NIH), Department of Health and Human Services (HHS)
Postdoctoral Scientist (m / f) Cancer Immunology
Boehringer Ingelheim
More Science jobs from
Nature Reviews Immunology
Frontiers in Cancer Immunotherapy
New York, USA
More science events from
Nature Outlook: Cancer immunotherapy 

Drugs that mobilize our immune systems against cancer are dramatically improving care for many people, and research is rapidly moving ahead in the lab and the clinic. 

Access this Outlook free >>

Produced with support from 
F. Hoffmann-La Roche Ltd  

Produced with support of a grant from Merck & Co., Inc.
  Focus on: Cancer immunotherapy
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe & Kristen E. Pauken

p153 | doi:10.1038/nri.2017.108
In this Review, the authors detail the complex expression patterns and regulation of programmed cell death protein 1 (PD1) and its ligands. The authors focus on the importance of understanding these pathways in order to optimize the efficiency and safety of immune checkpoint blockade in patients.
Abstract | Full Text | PDF

Towards personalized, tumour-specific, therapeutic vaccines for cancer
Zhuting Hu, Patrick A. Ott & Catherine J. Wu

p168 | doi:10.1038/nri.2017.131
Recent studies showing that neoantigens are crucial targets of the antitumour immune response have supported the progression of personalized cancer vaccines to clinical trials.
Abstract | Full Text | PDF

The dawn of vaccines for cancer prevention
Olivera J. Finn

p183 | doi:10.1038/nri.2017.140
Heeding the adage “prevention is better than cure”, Olivera J. Finn proposes that vaccinating individuals who have pre-malignant lesions gives the immune system the upper hand and can prevent progression to cancer.
Abstract | Full Text | PDF

Online-only and open access, npj Primary Care Respiratory Medicine is the only fully-indexed scientific journal devoted to the management of respiratory diseases in primary care.
Explore the benefits of submitting your next research article.
  Focus on: Cancer immunotherapy
Improving immune–vascular crosstalk for cancer immunotherapy
Yuhui Huang, Betty Y. S. Kim, Charles K. Chan, Stephen M. Hahn, Irving L. Weissman & Wen Jiang

p195 | doi:10.1038/nri.2017.145
Normalization of the tumour vasculature can improve immune effector cell infiltration, leading to immunotherapy potentiation. In this Opinion article, Huang et al. propose that reciprocal regulation between tumour vascular normalization and immune reprogramming forms a positive feedback loop that can induce durable antitumour immunity within the tumour microenvironment.
Abstract | Full Text | PDF

The tumour glyco-code as a novel immune checkpoint for immunotherapy
Ernesto RodrIguez, Sjoerd T. T. Schetters & Yvette van Kooyk

p204 | doi:10.1038/nri.2018.3
Could the specific glycosylation signatures associated with tumour cells be harnessed for immunotherapy purposes? In this Opinion, the authors propose that the tumour glyco-code may represent a novel immune checkpoint that could be targeted in the clinic.
Abstract | Full Text | PDF | Supplementary information

Synthetic immune niches for cancer immunotherapy
Jorieke Weiden, Jurjen Tel & Carl G. Figdor

p212 | doi:10.1038/nri.2017.89
Carl Figdor and colleagues propose that delivering cancer immunotherapy in the context of engineered three-dimensional scaffolds may boost anticancer immunity. The synthetic scaffolds, which can be linked to immunomodulatory factors, can act as immune niches to support the priming and maintenance of antitumour immune responses.
Abstract | Full Text | PDF

Foreign antigen-independent memory-phenotype CD4+ T cells: a new player in innate immunity?
Takeshi Kawabe, Jinfang Zhu & Alan Sher

p219 | doi:10.1038/nri.2018.12
Full Text | PDF
Foreign antigen-independent memory-phenotype CD4+ T cells: a new player in innate immunity?
Ross M. Kedl & Jason T. White

p219 | doi:10.1038/nri.2018.13
Full Text | PDF
Erratum: Regulation of T cell signalling by membrane lipids
Wei Wu, Xiaoshan Shi & Chenqi Xu

p219 | doi:10.1038/nri.2018.9
Full Text | PDF
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions.
Explore the benefits of submitting your next manuscript to the journal.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events


You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at:
(You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: